Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Introduction: This study evaluated the cost-effectiveness of atezolizumab + chemotherapy vs. chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC) in the United States (US).Methods: The three health states partitioned survival (PS) model was used over the lifetime. E...

Full description

Bibliographic Details
Main Authors: Yingcheng Wang, Mingjun Rui, Lan Yang, Xintian Wang, Ye Shang, Aixia Ma, Hongchao Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Public Health
Subjects:
small-cell lung cancer
cost-effectiveness
atezolizumab
chemotherapy
extensive stage
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2021.650392/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2021.650392/full

Similar Items